RxDoctor Payments Data

Binu Shajimon

Acute Care · Philadelphia, PANPI 1922322197

Payments from drug & device makers

$1,986in general payments, 2019–2025

Across 60 payments — averaging $33.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$658
  • E.r. Squibb & Sons, L.L.C.$417
  • Pfizer$246
  • Novo Nordisk$142
  • Novartis$101
  • Boston Scientific$80
  • plus $342 from 11 others

What the payments were for

  • Food & beverage$1,95098%
  • Education$362%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,986 in reported general payments places this provider in the 85th percentile of 872 acute care providers in Pennsylvania.

See all acute care providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$3,543
Medicare patients
21
Services billed
41

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrilintaTicagrelor42$38,155
EliquisApixaban22$19,317
Repatha SureclickEvolocumab19$11,863
Ranolazine ErRanolazine12$2,605
ClopidogrelClopidogrel Bisulfate134$2,435
Atorvastatin Calcium126$1,980
Ezetimibe43$1,328
Rosuvastatin Calcium44$1,250
Nifedipine ErNifedipine36$1,172
Metoprolol Succinate46$768
Losartan Potassium45$675
Carvedilol75$563
Amlodipine Besylate67$561
Isosorbide Mononitrate ErIsosorbide Mononitrate33$506
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide14$435

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$28$38,15542 claims
PfizerEliquis$246$19,31722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 872 acute care providers in Pennsylvania.

Other acute care in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →